View ValuationVoyager Acquisition 将来の成長Future 基準チェック /06現在、 Voyager Acquisitionの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Capital Markets 収益成長11.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 17Voyager Acquisition Corp. announced delayed 10-Q filingOn 05/15/2026, Voyager Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 25Veraxa Biotech AG entered into a definitive business combination agreement to acquire Voyager Acquisition Corp. (NasdaqGM:VACH) from Voyager Acquisition Sponsor Holdco LLC and others for approximately $1.4 billion in a reverse merger transaction.Veraxa Biotech AG entered into a definitive business combination agreement to acquire Voyager Acquisition Corp. (NasdaqGM:VACH) from Voyager Acquisition Sponsor Holdco LLC and others for approximately $1.4 billion in a reverse merger transaction on April 22, 2025. Under the terms of the Business Combination Agreement, VERAXA’s equity value contribution into the Business Combination will amount to approximately $1.3 billion. Accordingly, VERAXA’s shareholders will receive approximately 130 million ordinary shares of the combined company in exchange for their existing VERAXA shares. Existing VERAXA shareholders and management will not receive any cash proceeds as part of the transaction and will roll over 100% of their equity into the combined company. In accordance with the terms and subject to the conditions of the Business Combination Agreement, (i) each issued and outstanding ordinary share in the Company will be cancelled and exchanged for the fraction of a PubCo Class A ordinary share equal to the Exchange Ratio (as defined in the Business Combination Agreement); (ii) (x) each issued and outstanding SPAC Unit will be automatically detached and the holder will be deemed to hold one SPAC Class A ordinary share and one-half of a SPAC warrant and (y) each issued and outstanding SPAC Class A ordinary share and SPAC Class B ordinary share will be cancelled and exchanged for one PubCo Class A ordinary share; and (iii) each issued and outstanding whole SPAC warrant will be converted into a whole warrant to purchase one PubCo Class A ordinary share. In addition to the consideration described above, the Company Shareholders shall have the right to receive an aggregate of up to 5,000,000 PubCo Class A Ordinary Shares (the “Earnout Shares”) during each of the three fiscal years after the Closing Date in accordance with Section 2.8 of the Business Combination Agreement and applicable Swiss Law. Post acquiistion completion, VERAXA Biotech shareholders will own 79.2% stake, SPAC shareholders will own 15.4%, sponsor shares will be 3.9% and PIPE shareholders will own 1.5%. In the event that the Business Combination Agreement is terminated by SPAC pursuant to Section 10.1(g) or Section 10.1(i) of the Business Combination Agreement, the Company shall pay to SPAC a termination fee of $12,500,000 within five (5) Business Days following such termination; provided, that to the extent the Business Combination Agreement is terminated and (i) it is concurrently or subsequently discovered by SPAC or that the Company breached Section 6.3 of the Business Combination Agreement prior to any such termination or enters into any written agreement to participate in an alternative transaction, then in addition any termination fee payment owing to SPAC, the Company shall pay to SPAC the greater of (A) $12,500,000 and (B) 1% of the enterprise value of such alternate transaction. The boards of directors of both Voyager and VERAXA have unanimously approved the Business Combination. The transaction is subject to approval of Voyager’s and VERAXA’s shareholders and the satisfaction of certain other customary closing conditions, including but not limited to, (i) the Registration Statement has become effective, PubCo’s listing application with Nasdaq is approved and, the PubCo Class A ordinary shares to be issued in connection with the Business Combination shall have been approved for listing on Nasdaq, subject to official notice of issuance, the absence of a legal prohibition on consummating the transaction, compliance by Sponsor with certain provisions in the Sponsor Support Agreement, compliance by the Company Shareholders with certain provisions in the Shareholder Support Agreement and the delivery of customary certificates and ancillary agreements. Voyager and VERAXA expect the Business Combination to close in the fourth quarter of 2025. Anne Martina Group acted as financial advisor and Andrew Tucker of Duane Morris LLP acted as legal advisor for Veraxa Biotech AG. Michael J. Blankenship of Winston & Strawn LLP acted as legal advisor for Voyager Acquisition Corp. Claudio Bazzi of Bratschi AG acted as legal advisor to Voyager Acquisition. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Voyager Acquisition は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NasdaqGM:VACH - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2026N/A722N/A12/31/2025N/A900N/A9/30/2025N/A10-2-2N/A6/30/2025N/A9-3-3N/A3/31/2025N/A7-3-3N/Aアナリストによる今後の成長予測収入対貯蓄率: VACHの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: VACHの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: VACHの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: VACHの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: VACHの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: VACHの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YDiversified-financials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 23:16終値2026/05/26 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Voyager Acquisition Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 17Voyager Acquisition Corp. announced delayed 10-Q filingOn 05/15/2026, Voyager Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 25Veraxa Biotech AG entered into a definitive business combination agreement to acquire Voyager Acquisition Corp. (NasdaqGM:VACH) from Voyager Acquisition Sponsor Holdco LLC and others for approximately $1.4 billion in a reverse merger transaction.Veraxa Biotech AG entered into a definitive business combination agreement to acquire Voyager Acquisition Corp. (NasdaqGM:VACH) from Voyager Acquisition Sponsor Holdco LLC and others for approximately $1.4 billion in a reverse merger transaction on April 22, 2025. Under the terms of the Business Combination Agreement, VERAXA’s equity value contribution into the Business Combination will amount to approximately $1.3 billion. Accordingly, VERAXA’s shareholders will receive approximately 130 million ordinary shares of the combined company in exchange for their existing VERAXA shares. Existing VERAXA shareholders and management will not receive any cash proceeds as part of the transaction and will roll over 100% of their equity into the combined company. In accordance with the terms and subject to the conditions of the Business Combination Agreement, (i) each issued and outstanding ordinary share in the Company will be cancelled and exchanged for the fraction of a PubCo Class A ordinary share equal to the Exchange Ratio (as defined in the Business Combination Agreement); (ii) (x) each issued and outstanding SPAC Unit will be automatically detached and the holder will be deemed to hold one SPAC Class A ordinary share and one-half of a SPAC warrant and (y) each issued and outstanding SPAC Class A ordinary share and SPAC Class B ordinary share will be cancelled and exchanged for one PubCo Class A ordinary share; and (iii) each issued and outstanding whole SPAC warrant will be converted into a whole warrant to purchase one PubCo Class A ordinary share. In addition to the consideration described above, the Company Shareholders shall have the right to receive an aggregate of up to 5,000,000 PubCo Class A Ordinary Shares (the “Earnout Shares”) during each of the three fiscal years after the Closing Date in accordance with Section 2.8 of the Business Combination Agreement and applicable Swiss Law. Post acquiistion completion, VERAXA Biotech shareholders will own 79.2% stake, SPAC shareholders will own 15.4%, sponsor shares will be 3.9% and PIPE shareholders will own 1.5%. In the event that the Business Combination Agreement is terminated by SPAC pursuant to Section 10.1(g) or Section 10.1(i) of the Business Combination Agreement, the Company shall pay to SPAC a termination fee of $12,500,000 within five (5) Business Days following such termination; provided, that to the extent the Business Combination Agreement is terminated and (i) it is concurrently or subsequently discovered by SPAC or that the Company breached Section 6.3 of the Business Combination Agreement prior to any such termination or enters into any written agreement to participate in an alternative transaction, then in addition any termination fee payment owing to SPAC, the Company shall pay to SPAC the greater of (A) $12,500,000 and (B) 1% of the enterprise value of such alternate transaction. The boards of directors of both Voyager and VERAXA have unanimously approved the Business Combination. The transaction is subject to approval of Voyager’s and VERAXA’s shareholders and the satisfaction of certain other customary closing conditions, including but not limited to, (i) the Registration Statement has become effective, PubCo’s listing application with Nasdaq is approved and, the PubCo Class A ordinary shares to be issued in connection with the Business Combination shall have been approved for listing on Nasdaq, subject to official notice of issuance, the absence of a legal prohibition on consummating the transaction, compliance by Sponsor with certain provisions in the Sponsor Support Agreement, compliance by the Company Shareholders with certain provisions in the Shareholder Support Agreement and the delivery of customary certificates and ancillary agreements. Voyager and VERAXA expect the Business Combination to close in the fourth quarter of 2025. Anne Martina Group acted as financial advisor and Andrew Tucker of Duane Morris LLP acted as legal advisor for Veraxa Biotech AG. Michael J. Blankenship of Winston & Strawn LLP acted as legal advisor for Voyager Acquisition Corp. Claudio Bazzi of Bratschi AG acted as legal advisor to Voyager Acquisition.